拓扑替康联合顺铂治疗小细胞肺癌的近期疗效  

Evaluation of topotecan combined with cisplatin in the treatment of small cell lung cancer

作　　者：张智慧[1] 胡章华[2] 卢晓晖[1] 曾令源[1] 

机构地区：[1]四川省肿瘤医院内科,成都610041 [2]四川省内江市第二人民医院内一科

出　　处：《中国肺癌杂志》2002年第5期354-356,共3页Chinese Journal of Lung Cancer

摘　　要：目的　观察拓扑替康加顺铂联合方案对小细胞肺癌的疗效和毒性反应。方法　经病理组织学或细胞学证实的 2 6例小细胞肺癌应用拓扑替康 1.2 5mg/(m2 ·d) ,连用 5天 ,顺铂 2 5mg/(m2 ·d) ,连用 3天 ,2 1天为一周期 ,至少应用 2个周期。结果　全组 2 6例可评价病例中 ,CR 3例 ,PR 11例 ,SD 7例 ,PD 5例 ,总有效率为 5 3.8%。 12例初治患者中 ,CR 2例 ,PR 7例 ,SD 2例 ,PD 1例 ,有效率为 75 .0 % ;14例复治患者中 ,CR 1例 ,PR 4例 ,SD 5例 ,PD 4例 ,有效率为 35 .7%。 5例脑转移患者中 1例获PR。中位生存期 2 7周 ,1年生存率为 38.5 % ( 10 /2 6 )。主要不良反应为骨髓抑制。结论　拓扑替康联合顺铂治疗小细胞肺癌有较好的近期疗效 。Objective To evaluate the effects and toxicities of topotecan combined with cisplatin in the treatment of small cell lung cancer (SCLC). Methods Twenty-six patients with SCLC diagnosed by pathologic or cytologic examination were treated with topotecan 1.25 mg/(m 2·d) on days 1-5 and cisplatin 25 mg/(m 2·d) on days 1-3. The chemotherapy was repeated every 21 days as a cycle. Results Out of 26 evaluable patients, 3 achieved complete response and 11 achieved partial response with an overall response rate of 53.8%. The response rates were 75.0% and 35.7% in 12 previously untreated patients and 14 patients with prior chemotherapy, respectively. In addition, one of eight refractory patients and two of five patients with brain metastasis got partial responses. The median survival period was 27 weeks and one-year survival rate was 38.5%. Myelosuppression was the major dose-limiting toxicity. Conclusion Topotecan combined with cisplatin is effective for SCLC and it toxicity is tolerable.

关 键 词：拓扑替康 顺铂 小细胞肺癌 治疗 

分 类 号：R734.2[医药卫生—肿瘤]